Quarterly report pursuant to Section 13 or 15(d)

Description of Business (Details)

v2.4.0.6
Description of Business (Details)
Sep. 30, 2012
Description of Business [Abstract]  
Number classes of preclinical antibodies 3
Number of product candidates on rights to develop and commercialize 1
Number of product candidates on option to develop and commercialize 2